- Genmab A/S (NASDAQ:GMAB) announces the initiation of a 480-subject Phase 3 clinical trial comparing bispecific antibody (simultaneously binds to CD3 and CD20) epcoritamab to chemo in patients with diffuse large B-cell lymphoma (DLBCL). The primary endpoint is overall survival.
- The company is co-developing the candidate with AbbVie (NYSE:ABBV) under an agreement inked five months ago.
- https://seekingalpha.com/news/3632235-genmab-to-launch-late-stage-study-of-epcoritamab-in-aggressive-type-of-lymphoma
Thursday, November 5, 2020
Genmab to launch late-stage study of epcoritamab in aggressive type of lymphoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.